Equities researchers at Canaccord Genuity Group assumed coverage on shares of Arcellx (NASDAQ:ACLX – Get Rating) in a research note issued to investors on Wednesday, Briefing.com reports. The brokerage set a “buy” rating and a $32.00 price target on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 60.72% from the company’s previous close.
Separately, SVB Leerink dropped their price objective on shares of Arcellx from $47.00 to $38.00 and set an “outperform” rating on the stock in a research note on Thursday, June 23rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $31.50.
Arcellx Stock Performance
Shares of NASDAQ ACLX opened at $19.91 on Wednesday. Arcellx has a 1 year low of $6.03 and a 1 year high of $26.91. The company’s 50-day moving average is $15.63.
Insider Buying and Selling
In related news, major shareholder Enterprise Associates 15 New acquired 312,500 shares of the stock in a transaction that occurred on Tuesday, June 21st. The shares were bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the insider now directly owns 6,745,262 shares in the company, valued at $107,924,192. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACLX. SR One Capital Management LP bought a new position in Arcellx during the first quarter valued at approximately $77,110,000. Novo Holdings A S purchased a new stake in Arcellx during the first quarter valued at approximately $56,317,000. Suvretta Capital Management LLC purchased a new stake in Arcellx during the first quarter valued at approximately $21,493,000. AJU IB Investment Co. Ltd. purchased a new stake in Arcellx during the first quarter valued at approximately $19,360,000. Finally, BlackRock Inc. purchased a new stake in Arcellx during the first quarter valued at approximately $7,012,000. Institutional investors own 44.64% of the company’s stock.
Arcellx, Inc, a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
- Get a free copy of the StockNews.com research report on Arcellx (ACLX)
- Salesforce Stock is a Resilient Best-of Breed CRM Play
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Use High Beta Stocks to Maximize Your Investing Profits
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Why Will Highly-Valued Tesla Move Higher? Results
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.